Home › Funds › Prosight Management, LP › ALNY
Prosight Management, LP position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Prosight Management, LP reported holding 37,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$9.1M, representing 1.77% of its reported portfolio and ranking #19 among its reported holdings. Prosight Management, LP has disclosed ALNY holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Prosight Management, LP's ALNY position evolved
Prosight Management, LP first disclosed a stake in ALNY in Q4 2025 at 17,109 shares (US$6.8M). The position peaked in Q2 2026 at 98,080 shares, worth US$29.5M. Across 4 filings, Prosight Management, LP increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 37,000 shares valued at US$9.1M — a reduction of -61,080 shares quarter over quarter.. Notable position changes include a 344% increase in Q1 2026 (shares fell 8% over the following quarter), a 29% increase in Q2 2026 (shares fell 19% over the following quarter), a 62% trim in Q3 2026 (shares fell 33% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 17.11K | $6.80M | New |
| Q1 2026 | 76.00K | $25.15M | Add |
| Q2 2026 | 98.08K | $29.53M | Add |
| Q3 2026 | 37.00K | $9.13M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$1.36B), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 5.49M sh · $1.36B · Q3 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
More on Prosight Management, LP
FAQ
How long has Prosight Management, LP held ALNY?
Prosight Management, LP has disclosed ALNY holdings in 4 of the last 4 reported quarters, going back to Q4 2025.
What is Prosight Management, LP's current position in ALNY?
As of Q3 2026, Prosight Management, LP holds 37.00K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $9.13M, representing 1.77% of its reported portfolio and ranking #19.
Has Prosight Management, LP been buying or selling ALNY?
In the latest 13F filing (Q3 2026), Prosight Management, LP reduced its position in ALNY. The position peaked in Q2 2026 at 98.08K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 30 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.